Here is the point: Where there is a lower baseline risk, like risk of hospitalization or death in patients with covid, the higher sample size you need to have reasonable statistical power. If the baseline risk is higher, as it is with ventilated ARDS patients, you can have that statistical power with a smaller sample size.
- Forums
- ASX - By Stock
- MSB
- New Covid 19 treatment
New Covid 19 treatment, page-301
-
-
- There are more pages in this discussion • 144 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
97.5¢ |
Change
0.015(1.56%) |
Mkt cap ! $1.118B |
Open | High | Low | Value | Volume |
97.0¢ | 99.5¢ | 97.0¢ | $969.4K | 987.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 494 | 97.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
98.0¢ | 61712 | 27 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 18421 | 0.975 |
15 | 141760 | 0.970 |
14 | 336113 | 0.965 |
9 | 545629 | 0.960 |
3 | 26200 | 0.955 |
Price($) | Vol. | No. |
---|---|---|
0.980 | 69443 | 27 |
0.985 | 37054 | 11 |
0.990 | 114452 | 12 |
0.995 | 135098 | 15 |
1.000 | 98225 | 8 |
Last trade - 10.59am 22/08/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |